Try LifeScience Products:
AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
86
K
Drugs & Biologics
46
K
Targets
978
K
Organizations
922
K
/
171
K
Clinical Trials / Results
66
M
Literatures
16
M
Patents
Recent blog posts
View all blog posts →
Cidara Therapeutics Retakes Global Rights to CD388, Initiates $240M Funding Drive
Latest Hotspot
3 min read
Cidara Therapeutics Retakes Global Rights to CD388, Initiates $240M Funding Drive
28 April 2024
Cidara Therapeutics regains worldwide control for developing and marketing CD388, also launches a $240 million private funding initiative.
Read →
Sosei Heptares has been renamed Nxera Pharma, with updates made to its corporate structure
Hot Spotlight
3 min read
Sosei Heptares has been renamed Nxera Pharma, with updates made to its corporate structure
28 April 2024
On March 27th, Japan's Sosei Group Corporation announced that their board members and executives were reelected during the 34th Annual General Meeting and subsequent board meeting in Tokyo.
Read →
FDA Prioritizes GSK's Proposal to Expand Jemperli Use with Chemotherapy in Advanced Endometrial Cancer
Latest Hotspot
3 min read
FDA Prioritizes GSK's Proposal to Expand Jemperli Use with Chemotherapy in Advanced Endometrial Cancer
28 April 2024
FDA has prioritized GSK’s submission to broaden the use of Jemperli (dostarlimab) with chemotherapy for treating all adult patients with initial advanced or relapsed endometrial cancer.
Read →
Check out our latest report
View all reports →
Global Drug R&D Express (Jan 2024)

Global Drug R&D Express (Jan 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 68 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Global Drug R&D Express (Dec 2023)

Global Drug R&D Express (Dec 2023)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 104 drugs. Among them, 2 first-to-market drugs and 5 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Global Drug R&D Express (Nov 2023)

Global Drug R&D Express (Nov 2023)

This report compiles and summarizes the basic information of all the first-to-market and special-review medicines globally in November, totaling 104. From these, 5 first-to-market medicines and 5 special-review medicines have been meticulously selected. The report provides a detailed interpretation of these medicines, covering multiple aspects such as their basic information, development status, technological barriers, mechanisms of action, clinical trials, and competitive landscape.

Read →
Latest news
View all news →
news cover
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
5 hours ago
news cover
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
26 Apr 2024
news cover
Starton Therapeutics Announces Enrollment Completion for STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma
26 Apr 2024
news cover
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
26 Apr 2024
Who We Serve
View our solutions →
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
LifeScience Product Suite
Synapse
Looking for drug development opportunities
Evaluate the value of license-in projects
Screen investment targets
Optimize product pipeline
Current product
Bio
Chase new frontiers in bio-innovation
Stay on top of competitor movements
Validate novelty and freedom to operate searches with ease
Identify sequences for therapeutic activities
View details
Chemical
Explore promising compounds and their applications
Accelerate novelty and freedom to operate reviews
Strengthen competitor analysis
View details
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.